- Home
- PLD vs BMY Comparison
PLD vs BMY Comparison
Compare PLD & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLD | BMY |
|---|---|---|
| Founded | 1983 | 1887 |
| Country | United States | United States |
| Employees | N/A | 32500 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.7B | 123.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PLD | BMY |
|---|---|---|
| Price | $134.19 | $60.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 15 |
| Target Price | ★ $135.29 | $61.93 |
| AVG Volume (30 Days) | 2.6M | ★ 11.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 3.10% | ★ 4.15% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.41 | N/A |
| Revenue Next Year | $5.88 | N/A |
| P/E Ratio | $39.25 | ★ $17.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $85.35 | $42.52 |
| 52 Week High | $143.95 | $63.33 |
Technical Indicators
Market Signals| Indicator | PLD | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 42.55 | 52.06 |
| Support Level | $126.25 | $59.23 |
| Resistance Level | $134.94 | $62.05 |
| Average True Range (ATR) | 2.47 | 1.20 |
| MACD | -0.89 | -0.27 |
| Stochastic Oscillator | 13.39 | 25.02 |
Price Performance
Historical ComparisonAbout PLD Prologis Inc.
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1.3 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $60 billion of third-party assets under management. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.